Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 4/20 | 0.50 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
| ▸ | LTA4H | P09960 | 2/20 | 0.42 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | ACHE | P22303 | 1/20 | 0.41 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CSF3R | Q99062 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL609944 | 0.91 | TAAR1 (0.47) | TAAR1KCNH2LTA4HMAPK1L3MBTL1 | |
| SCHEMBL28032739 | 0.88 | TAAR1 (0.58) | TAAR1TSHRMAPK1TDP1L3MBTL1 | |
| SCHEMBL611119 | 0.85 | TAAR1 (0.45) | TAAR1KCNH2LTA4HTSHRMAPK1 | |
| SCHEMBL2207505 | 0.85 | CSF3R (0.48) | TAAR1TSHRMAPK1TDP1L3MBTL1 | |
| SCHEMBL13072739 | 0.84 | SLC2A1 (0.50) | KCNH2L3MBTL1CYP2D6 | |
| SCHEMBL3228373 | 0.84 | TAAR1 (0.51) | TAAR1LTA4HTSHRMAPK1TDP1 | |
| SCHEMBL29819005 | 0.83 | TDP1 (0.53) | TAAR1LTA4HMAPK1TDP1L3MBTL1 | |
| SCHEMBL2208810 | 0.83 | TDP1 (0.53) | TAAR1LTA4HMAPK1TDP1L3MBTL1 | |
| SCHEMBL13862448 | 0.82 | TAAR1 (0.45) | TAAR1KCNH2LTA4HTSHRMAPK1 | |
| SCHEMBL611955 | 0.81 | TAAR1 (0.44) | TAAR1KCNH2TSHRMAPK1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11834460-B2 | Imide-based modulators of proteolysis and associated methods of use | YALE UNIVERSITY (US) | 2023-12-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11834460-B2 | Imide-based modulators of proteolysis and associated methods of use | CRBN, MDM2, UBE2N | TAAR1 4174/4885KCNH2 4858/4885LTA4H 2941/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.